- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc stock price live, this page displays NASDAQ BTAI stock exchange data. View the BTAI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BioXcel Therapeutics Inc real time stock price chart below.
What Is the BioXcel Therapeutics Inc Stock Price Today?
The BioXcel Therapeutics Inc stock price today is 4.045.
What Is the Stock Symbol for BioXcel Therapeutics Inc?
The stock symbol for BioXcel Therapeutics Inc is ""BTAI.""
What Stock Exchange Does BioXcel Therapeutics Inc Trade On?
BioXcel Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is BioXcel Therapeutics Inc a Good Stock to Buy?
Determining whether BioXcel Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BTAI quote. (ISIN: US09075P2048)
What Is the BioXcel Therapeutics Inc Stock Price Today?
The BioXcel Therapeutics Inc stock price today is 4.045.
What Is the Stock Symbol for BioXcel Therapeutics Inc?
The stock symbol for BioXcel Therapeutics Inc is ""BTAI.""
What Stock Exchange Does BioXcel Therapeutics Inc Trade On?
BioXcel Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is BioXcel Therapeutics Inc a Good Stock to Buy?
Determining whether BioXcel Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BTAI quote. (ISIN: US09075P2048)
4.045
-1.195(-22.81%)
Real-time Data·
Fair Value
An estimate of a BioXcel Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.930
5.190
52 wk Range
1.170
13.362
BTAI Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
Unusual trading volume
1/2
Fair Value
An estimate of a BioXcel Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.9305.190
52 wk Range
1.17013.362
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BTAI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a BioXcel Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
19.400
Upside
+379.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
BioXcel Therapeutics Inc Company Profile
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Compare BTAI to Peers and Sector
Metrics to compare | BTAI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBTAIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −1.2x | −0.5x | |
PEG Ratio | −0.02 | −0.05 | 0.00 | |
Price/Book | −0.7x | 1.7x | 2.6x | |
Price / LTM Sales | 87.9x | 8.2x | 3.3x | |
Upside (Analyst Target) | 90.8% | 280.7% | 38.7% | |
Fair Value Upside | Unlock | 28.0% | 5.0% | Unlock |
Analyst Ratings
3 Buy
1 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 19.400
(+379.60% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-2.45 / -0.13
Revenue / Forecast
120.00K / 400.00K
People Also Watch
FAQ
What Stock Exchange Does BioXcel Therapeutics Trade On?
BioXcel Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for BioXcel Therapeutics?
The stock symbol for BioXcel Therapeutics is "BTAI."
What Is the BioXcel Therapeutics Market Cap?
As of today, BioXcel Therapeutics market cap is 58.15M.
What Is BioXcel Therapeutics's Earnings Per Share (TTM)?
The BioXcel Therapeutics EPS (TTM) is -11.08.
From a Technical Analysis Perspective, Is BTAI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has BioXcel Therapeutics Stock Split?
BioXcel Therapeutics has split 1 times.
How Many Employees Does BioXcel Therapeutics Have?
BioXcel Therapeutics has 37 employees.
What is the current trading status of BioXcel Therapeutics (BTAI)?
As of 27 Aug 2025, BioXcel Therapeutics (BTAI) is trading at a price of 4.05, with a previous close of 5.24. The stock has fluctuated within a day range of 3.93 to 5.19, while its 52-week range spans from 1.17 to 13.36.
What Is BioXcel Therapeutics (BTAI) Price Target According to Analysts?
The average 12-month price target for BioXcel Therapeutics is USD19.4, with a high estimate of USD66 and a low estimate of USD1. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +379.60% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.